These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 22997974

  • 1. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
    Beiraghdar F, Panahi Y, Einollahi B, Nemati E, Ghadiani MH, Sahebkar A, Maghsoudi N, Marzony ET.
    Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
    [Abstract] [Full Text] [Related]

  • 2. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the correction of post-transplantation anemia: a randomized comparative trial with Eprex.
    Beiraghdar F, Panahi Y, Einollahi B, Torkaman M, Mohammadi R, Marzony ET, Sahebkar A.
    Clin Lab; 2012; 58(11-12):1179-85. PubMed ID: 23289187
    [Abstract] [Full Text] [Related]

  • 3. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU.
    Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
    [Abstract] [Full Text] [Related]

  • 4. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR.
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [Abstract] [Full Text] [Related]

  • 5. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
    Caramelo C, Soto C, Neira F, López MD, Jiménez S, Albalate M, de Oña R, Llamas P, Deudero JJ.
    Nefrologia; 2004 Oct; 24(4):351-6. PubMed ID: 15455495
    [Abstract] [Full Text] [Related]

  • 6. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF, Casanova-González M, García-García I, Porrero-Martín PJ, Valenzuela-Silva CM, Hernández-Montero T, Lagarde-Ampudia M, Casanova-Kutsareva Y, Avila-Albuerne Y, Vargas-Batista A, Bobillo-López H, Herrera-Valdés R, López-Saura PA, Bioequivalence Study of Erythropoietin Group.
    BMC Nephrol; 2005 May 23; 6():5. PubMed ID: 15910687
    [Abstract] [Full Text] [Related]

  • 7. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O, Feldman J, Friedman EA.
    N Engl J Med; 1996 Feb 15; 334(7):420-5. PubMed ID: 8552143
    [Abstract] [Full Text] [Related]

  • 8. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW.
    N Engl J Med; 1987 Jan 08; 316(2):73-8. PubMed ID: 3537801
    [Abstract] [Full Text] [Related]

  • 9. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.
    Ther Apher Dial; 2010 Jun 08; 14(3):240-75. PubMed ID: 20609178
    [Abstract] [Full Text] [Related]

  • 10. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis.
    Thitiarchakul S, Tasanarong A.
    J Med Assoc Thai; 2007 Apr 08; 90(4):636-42. PubMed ID: 17487116
    [Abstract] [Full Text] [Related]

  • 11. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
    Abbas EE, Afioni N, Al Wakeel J, Bakr MA, Dham R, Donia A, Droubi N, Khidir E, Mathew CM, Mitwali AH, Naga S, Pingle A, Rashed A, Roshdy A, Shaheen F, Shaibani B, Shaibani FM, Shaker DS, Sheiban A, Solieman M.
    Transplant Proc; 2004 Apr 08; 36(6):1805-11. PubMed ID: 15350482
    [Abstract] [Full Text] [Related]

  • 12. Anemia of chronic renal failure: treatment with erythropoietin.
    Navarro M, Alonso A, Avilla JM, Espinosa L.
    Child Nephrol Urol; 1991 Apr 08; 11(3):146-51. PubMed ID: 1777893
    [Abstract] [Full Text] [Related]

  • 13. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H, Mimura T, Honda N.
    Hemodial Int; 2008 Oct 08; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [Abstract] [Full Text] [Related]

  • 14. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W, Egrie JC, Browne JK, Downing MR, Eschbach W.
    Behring Inst Mitt; 1988 Aug 08; (83):188-92. PubMed ID: 3071336
    [Abstract] [Full Text] [Related]

  • 15. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R.
    Semin Nephrol; 1989 Mar 08; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [Abstract] [Full Text] [Related]

  • 16. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H, Wang SX.
    Blood Purif; 2008 Mar 08; 26(2):151-6. PubMed ID: 18212498
    [Abstract] [Full Text] [Related]

  • 17. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K, Onoyama K, Iseki K, Fujimi S, Fujishima M.
    Clin Nephrol; 1990 Jun 08; 33(6):293-8. PubMed ID: 2376091
    [Abstract] [Full Text] [Related]

  • 18. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
    Hotta T, Ogawa H, Saito A, Ito A.
    Int J Hematol; 1991 Jun 08; 54(3):195-200. PubMed ID: 1747454
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
    de Sousa FT, Prata MM, Barbas JV, dos Santos JP.
    Acta Med Port; 1990 Jun 08; 3(6):347-52. PubMed ID: 2089856
    [Abstract] [Full Text] [Related]

  • 20. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN, Sinha DK, Almeida AF, Pathare AV.
    J Assoc Physicians India; 1995 Aug 08; 43(8):539-42. PubMed ID: 8772973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.